Does insulin resistance and high insulin reduce SHBG production and lower circulating SHBG levels?

Sex hormone-binding globulin (SHBG) is a major glycoprotein synthesized by the liver that regulates the bioavailability of sex steroids. During the menopausal transition, metabolic changes such as increased insulin resistance can significantly alter this regulatory pathway.

Mechanistic pathway of SHBG downregulation

• Transcriptional suppression: Hyperinsulinemia and insulin resistance directly suppress hepatic SHBG synthesis at the transcriptional level in hepatocytes.
• Transcription factor inhibition: This downregulation is primarily mediated by a reduction in hepatocyte nuclear factor 4-alpha (HNF4α) activity. HNF4α is a critical liver transcription factor required for driving SHBG promoter activity. When insulin levels are chronically elevated, HNF4α expression and activity are impaired, directly halting the transcription of the SHBG gene.

Clinical evidence and metabolic consequences

• Systemic decline: Because the liver is the primary source of circulating SHBG, decreased hepatic synthesis leads directly to lower systemic SHBG concentrations.
• Marker of metabolic health: In clinical studies, low circulating SHBG is a robust biomarker for insulin resistance, metabolic syndrome, and type 2 diabetes.
• Hormonal imbalance: In females, particularly around the age of menopause, a decline in SHBG increases the free fraction of testosterone and estradiol. This exacerbates androgenic symptoms and metabolic dysfunction, creating a reciprocal cycle where low SHBG and insulin resistance worsen each other.
• Reversibility: Clinical trials demonstrate that interventions improving insulin sensitivity—such as metformin therapy, weight loss, and dietary modifications—effectively restore hepatic HNF4α activity and increase systemic SHBG levels.

Bottom line

• Chronic insulin resistance and hyperinsulinemia directly suppress hepatic SHBG production by downregulating the key transcription factor HNF4α, leading to a significant reduction in systemic SHBG concentrations and an increase in bioavailable active androgens.